2-溴-1-(2,3-二氢-1-苯并呋喃-5-基)乙酮 | 151427-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2-溴-1-(2,3-二氢-1-苯并呋喃-5-基)乙酮
• 英文名称: 2-bromo-1-(2,3-dihydrobenzofuran-5-yl)ethanone
• 英文别名: 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone
• CAS: 151427-19-9
• 化学式: C₁₀H₉BrO₂
• mdl: MFCD08444468
• 分子量: 241.084
• InChiKey: CZRHIPGIDWESKD-UHFFFAOYSA-N

物化性质

• 沸点：
  356.4±37.0 °C(Predicted)
• 密度：
  1.562±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone
CAS number: 151427-19-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9BrO2
Molecular weight: 241.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-(2,3-二氢-1-苯并呋喃-5-基)乙酮 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 17.5h， 生成 达非那新
  参考文献：
  名称：

  A New Solvent System (Cyclopentyl Methyl Ether–Water) in Process Development of Darifenacin HBr

  摘要：

  Darifenacin is a potent and competitive M-3 selective receptor antagonist (M(3)SRA), and its hydrobromide salt (1) is the active ingredient of pharmaceutical formulations for oral treatment of urinary incontinence. The present work demonstrates an efficient, commercial manufacturing process for darifenacin hydrobromide (1).

  DOI：

  10.1021/op300119s
• 作为产物：
  描述：

  2,3-二氢苯并呋喃 在 aluminum (III) chloride 、 对甲苯磺酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.5h， 生成 2-溴-1-(2,3-二氢-1-苯并呋喃-5-基)乙酮
  参考文献：
  名称：

  A New Solvent System (Cyclopentyl Methyl Ether–Water) in Process Development of Darifenacin HBr

  摘要：

  Darifenacin is a potent and competitive M-3 selective receptor antagonist (M(3)SRA), and its hydrobromide salt (1) is the active ingredient of pharmaceutical formulations for oral treatment of urinary incontinence. The present work demonstrates an efficient, commercial manufacturing process for darifenacin hydrobromide (1).

  DOI：

  10.1021/op300119s

文献信息

• One-Pot Preparation of Aromatic Amides, 4-Arylthiazoles, and 4-Arylimidazoles from Arenes
  作者：Takahiro Yamamoto、Hideo Togo

  DOI：10.1002/ejoc.201800730

  日期：2018.8.15

  Primary aromatic amides, 4‐arylthiazoles, and 4‐arylimidazoles were smoothly obtained from arenes in good yield in one pot via aryl α‐bromoacetylarenes, which were obtained by reacting simple arenes with α‐bromoacetyl chloride and AlCl3, followed by the reaction with molecular iodine and aq. NH3, thioamides, or amidine under transition‐metal‐free conditions.

  一锅中通过芳基α-溴乙酰芳烃轻松从芳烃中以高收率顺利获得伯芳族酰胺，4-芳基噻唑和4-芳基咪唑，这些芳烃是通过将简单的芳烃与α-溴乙酰氯和AlCl 3反应，然后与分子碘和水溶液 在无过渡金属的条件下，NH 3，硫酰胺或am。
• DIAMINOTHIAZOLES
  申请人：——

  公开号：US20040006058A1

  公开（公告）日：2004-01-08

  The present invention is directed to novel diaminothiazoles of formula 1 These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型的formula1的二氨基噻唑化合物。这些化合物抑制细胞周期依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面具有用途。本发明还涉及含有这些化合物的药物组合物，以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤的方法。
• Design, synthesis and structure–activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs
  作者：Shigeo Hayashi、Naomi Ueno、Akio Murase、Junji Takada

  DOI：10.3109/14756366.2013.864650

  日期：2014.12

  lung, liver, pancreas, breast, prostate, cervical and ovarian cancers are significant. In this study, design, synthesis and structure-activity relationship (SAR) of various novel 2-[(2-, 3- and/or 4-substituted)-benzoyl, (bicyclic heterocycloalkanophenyl)carbonyl or cycloalkanecarbonyl]-(5- or 6-substituted)-1H-indol-3-yl}acetic acid analogues were investigated to seek and identify various chemotypes

  由于环氧合酶（COX）在炎症过程中的关键作用，抑制COX活性的非甾体类抗炎药（NSAIDs）已在临床上用于治疗炎症性疾病/综合征。然而，传统的非甾体类抗炎药由于抑制COX-1而表现出严重的副作用，如胃肠道损害和超敏反应。同样，COX-2抑制性对各种癌症/肿瘤（例如结肠癌，胃癌，皮肤癌，皮肤癌，肺癌，肝癌，胰腺癌，乳腺癌，前列腺癌，宫颈癌和卵巢癌）的起始/增殖/侵袭/运动/复发/转移的抑制或预防作用癌症很重要。在这项研究中，设计，合成和各种新型2-[（2-，3-和/或4-取代）-苯甲酰基，结构-活性关系（SAR）（双环杂环烷苯基）羰基或环烷羰基]-（5-或6-取代）-1H-吲哚-3-基}乙酸类似物的研究旨在寻找和鉴定各种有效的和选择性的COX-2抑制剂，用于治疗炎症疾病，导致在外周炎症模型大鼠中发现口服有效药物。SAR和类似物的理化特性被描述为重要发现。有关图形摘要：请参阅补充材料。（www
• Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
  申请人：Pfizer Inc

  公开号：US06303628B1

  公开（公告）日：2001-10-16

  This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein A is C 1-6 alkylene or —NR1—; Z is C(═L)R2, or SO2R3; U is CH or N; W and Y are independently selected from —CH2—, O, S and —N—R1; m is 1, 2 or 3; q and r are independently 0, 1 or 2; X is independently selected from halogen, C1-4 alkyl, halo-substituted C1-4 alkyl, hydroxy, C1-4 alkoxy, halo-substituted C1-4 alkoxy or the like; n is 1 or 2; L is oxygen or sulfur; R1 is hydrogen or C1-4 alkyl; R2 is hydroxy, C1-6alkyl, halo-substituted C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C3-7 cycloalkoxy, C1-4 alkyl(C3-7 cycloalkoxy), —NR4R5 or the like; R3 is C1-6 alkyl or halo-substituted C1-6 alkyl; and R4 and R5 are independently selected from hydrogen, C1-6 alkyl and halo-substituted C1-6alkyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

  该发明提供了以下公式的化合物：或其药学上可接受的盐，其中A是C1-6烷基或—NR1—；Z是C(═L)R2，或SO2R3；U是CH或N；W和Y分别选择自—CH2—，O，S和—N—R1；m为1、2或3；q和r独立地为0、1或2；X独立地选择自卤素，C1-4烷基，卤代C1-4烷基，羟基，C1-4烷氧基，卤代C1-4烷氧基或类似物；n为1或2；L为氧或硫；R1为氢或C1-4烷基；R2为羟基，C1-6烷基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C3-7环烷氧基，C1-4烷基(C3-7环烷氧基)，—NR4R5或类似物；R3为C1-6烷基或卤代C1-6烷基；R4和R5独立地选择自氢，C1-6烷基和卤代C1-6烷基。该发明还提供了一种药物组合物，用于治疗前列腺素作为病原体参与的医疗状况。
• Substituted imidazo[1,2-A] pyridine derivatives
  申请人：——

  公开号：US20020188128A1

  公开（公告）日：2002-12-12

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列新颖的化合物，化学式为I，并通过给予有效治疗剂量的化合物化学式1来治疗或预防mGluR5受体介导的疾病的方法，其中R1和R2从氢、(C1-6)-烷基、卤素、羟基、(C1-6)-烷氧基中选择，A在描述中有定义，或其药用盐。